LIR Life Sciences Corp. SKNY
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -50.68% | -- | -- | -- | -- |
| Gross Profit | 50.68% | -- | -- | -- | -- |
| SG&A Expenses | 454.58% | 456.70% | 1,527.62% | 357.33% | 182.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 593.42% | 485.05% | 1,537.47% | 360.59% | 206.93% |
| Operating Income | -593.42% | -485.05% | -1,537.47% | -360.59% | -206.93% |
| Income Before Tax | -594.61% | -560.32% | -1,798.42% | -359.93% | -207.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -594.61% | -560.32% | -1,798.42% | -359.93% | -207.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -594.61% | -560.32% | -1,798.42% | -359.93% | -207.23% |
| EBIT | -593.42% | -485.05% | -1,537.47% | -360.59% | -206.93% |
| EBITDA | -598.02% | -- | -- | -- | -- |
| EPS Basic | -357.41% | -330.95% | -133.06% | 98.81% | 99.19% |
| Normalized Basic EPS | -352.94% | -296.23% | -138.41% | 98.80% | 99.18% |
| EPS Diluted | -357.41% | -330.95% | -133.06% | 98.81% | 99.19% |
| Normalized Diluted EPS | -352.94% | -296.23% | -138.41% | 98.80% | 99.18% |
| Average Basic Shares Outstanding | 50.88% | 53.71% | 714.97% | 38,689.00% | 37,900.00% |
| Average Diluted Shares Outstanding | 50.88% | 53.71% | 714.97% | 38,689.00% | 37,900.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |